# Developmental Funds

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2020 · $273,137

## Abstract

DEVELOPMENTAL FUNDS
ABSTRACT
Developmental Funds are an essential component of the UCLA Jonsson Comprehensive Cancer Center (JCCC)
total resource package that Center leadership allocates for strategic imperatives to bolster high priority science
and support the Center mission of accelerating discoveries to prevent and cure cancer.
Use of CCSG Developmental Funds targets priorities identified in the 2019 – 2023 JCCC Strategic Plan,
leveraging combinations of additional resources obtained from philanthropy, foundations, UCLA schools and
departments, and UCLA Health. Funds deployed for Center development initiatives that originate from the CCSG
and other sources support multiple activities that enhance impactful JCCC research in its Los Angeles County
catchment area and beyond. These deployments include funds for research faculty recruitment, for innovative
transdisciplinary research through the competitive JCCC Intramural Awards Program, and for key initiatives,
such as development of interventional early phase clinical research studies in identified high priority areas, or to
enhance health care access and reduce disparities for Los Angeles County residents.
To maximize the impact that leveraged Developmental Funds have on the Center and the community it serves,
the JCCC embraces two overarching specific aims. Aim 1 is to support cutting-edge cancer research as
prioritized by the 2019 – 2023 JCCC Strategic Plan through added resourcing of the competitive JCCC Intramural
Awards Program. Supported strategic goals include development of highly innovative interventional early phase
clinical studies in multiple tumor types informed through Center community outreach and engagement activities
that identify top community needs. Aim 2 is to leverage non-CCSG sources of support to fund additional
intramural awards and to support recruitment and retention of faculty in areas elevated by the Center Strategic
Plan. Areas identified as priorities include expanding clinical research and increasing inclusion of underserved
populations, continuing to strengthen the JCCC Oncology Clinical Trials Network, initiatives focused on obesity
and metabolism, translational theranostics, and cancer immunotherapy, as well as a focus on cancer biophysics
and device commercialization.

## Key facts

- **NIH application ID:** 9936726
- **Project number:** 2P30CA016042-44
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** MICHAEL A TEITELL
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $273,137
- **Award type:** 2
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9936726

## Citation

> US National Institutes of Health, RePORTER application 9936726, Developmental Funds (2P30CA016042-44). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9936726. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*